1 Sharon, N & Ofek, I (2000) Safe as mother's milk: carbohydrates as future anti-adhesion drugs for bacterial diseases. Glycoconj J 17, 659–664.
2 Kunz, C, Rudloff, S, Baier, W, Klein, N & Strobel, S (2000) Oligosaccharides in human milk: structural, functional, and metabolic aspects. Annu Rev Nutr 20, 699–722.
3 Bode, L, Kunz, C, Muhly-Reinholz, M, Mayer, K, Seeger, W & Rudloff, S (2004) Inhibition of monocyte, lymphocyte, and neutrophil adhesion to endothelial cells by human milk oligosaccharides. Thromb Haemost 92, 1402–1410.
4 Bode, L, Rudloff, S, Kunz, C, Strobel, S & Klein, N (2004) Human milk oligosaccharides reduce platelet–neutrophil complex formation leading to a decrease in neutrophil β2 integrin expression. J Leukocyte Biol 76, 1–7.
5 Kobata, A & Ginsburg, V (1972) Oligosaccharides of human milk. 3. Isolation and characterization of a new hexasaccharide, lacto-N-hexaose. J Biol Chem 247, 1525–1529.
6 Kobata, A, Yamashita, K & Tachibana, Y (1978) Oligosaccharides from human milk. Methods Enzymol 50, 216–220.
7 Kunz, C, Rudloff, S, Hintelmann, A, Pohlentz, G & Egge, H (1996) High-pH anion-exchange chromatography with pulsed amperometric detection and molar response factors of human milk oligosaccharides. J Chromatogr B Biomed Appl 25, 211–221.
8 Parkkinen, J & Finne, J (1987) Isolation of sialyl oligosaccharides and sialyl oligosaccharide phosphates from bovine colostrum and human urine. Methods Enzymol 138, 289–300.
9 Kunz, C & Rudloff, S (2000) Oligosaccharides in human milk: structural, functional and metabolic aspects. Annu Rev Nutr 20, 699–722.
10 Engfer, MB, Stahl, B, Finke, B, Sawatzki, G & Daniel, H (2000) Human milk oligosaccharides are resistant to enzymatic hydrolysis in the upper gastrointestinal tract. Am J Clin Nutr 71, 1589–1596.
11 Gnoth, MJ, Kunz, C, Kinne-Saffran, E & Rudloff, S (2000) Human milk oligosaccharides are minimally digested in vitro. J Nutr 130, 3014–3020.
12 Gnoth, MJ, Rudloff, S, Kunz, C & Kinne, RK (2001) Investigations of the in vitro transport of human milk oligosaccharides by a Caco-2 monolayer using a novel high performance liquid chromatography–mass spectrometry technique. J Biol Chem 14, 34363–34370.
13 Kuntz, S, Rudloff, S & Kunz, C (2008) Oligosaccharides from human milk influence growth-related characteristics of intestinally transformed and non-transformed intestinal cells. Br J Nutr 99, 462–471.
14 Vermeulen, K, Van Bockstaele, DR & Berneman, ZN (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36, 131–149.
15 Serrano, M (2003) Proliferation: the cell cycle. Adv Exp Med Biol 532, 13–17.
16 Stein, GH & Dulic, V (1998) Molecular mechanisms for the senescent cell cycle arrest. J Investig Dermatol Symp Proc 3, 14–18.
17 Dai, Y & Grant, S (2003) Cyclin-dependent kinase inhibitors. Curr Opin Pharmacol 3, 362–370.
18 Mani, S, Wang, C, Wu, K, Francis, R & Pestell, R (2000) Cyclin-dependent kinase inhibitors: novel anticancer agents. Expert Opin Investig Drugs 9, 1849–1870.
19 Baghdassarian, N & French, M (1996) Cyclin-dependent kinase inhibitors (CKIs) and hematological malignancies. Hematol Cell Ther 38, 152–158.
20 Li, Y, Dowbenko, D & Lasky, L (2002) AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem 17, 277–286.
21 Rudloff, S, Obermeier, S, Borsch, CH, Pohlentz, G, Hartmann, R, Brösicke, H, Lentze, MJ & Kunz, C (2006) Incorporation of orally applied 13C-galactose into milk lactose and oligosaccharides. Glycobiology 16, 477–487.
22 Perreault, N & Beaulieu, JF (1996) Use of the dissociating enzyme thermolysin to generate viable human normal intestinal epithelial cell cultures. Exp Cell Res 1, 354–364.
23 Nadella, KS & Kirschner, LS (2005) Disruption of protein kinase A regulation causes immortalization and dysregulation of D-type cyclins. Cancer Res 15, 10307–10315.
24 Ouyang, W, Ma, Q, Li, J, Zhang, D, Liu, ZG, Rustgi, AK & Huang, C (2005) Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res 15, 9287–9293.
25 Lewis, RC, Bostick, RM, Xie, D, Deng, Z, Wargovich, MJ, Fina, MF, Roufail, WM & Geisinger, KR (2003) Polymorphism of the cyclin D1 gene, CCND1, and risk for incident sporadic colorectal adenomas. Cancer Res 63, 8549–8553.
26 McKay, JA, Douglas, JJ, Ross, VG, Curran, S, Murray, GI, Cassidy, J & McLeod, HL (2000) Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Int J Cancer 88, 77–81.
27 Dash, BC & El-Deiry, WS (2005) Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol 25, 3364–3387.
28 Ji, P, Agrawal, S, Diederichs, S, et al. (2005) Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells. Oncogene 14, 2739–2744.
29 Li, R, Hannon, GJ, Beach, D & Stillman, B (1996) Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage. Curr Biol 6, 189–199.
30 Harper, JW, Elledge, SJ, Keyomarsi, K, et al. (1995) Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6, 387–400.
31 Sherr, CJ & Roberts, JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13, 1501–1512.
32 Blain, SW, Montalvo, E & Massagué, J (1997) Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. J Biol Chem 272, 25863–25872.
33 Matsui, TA, Sowa, Y, Murata, H, et al. (2007) The plant alkaloid cryptolepine induces p21WAF1/CIP1 and cell cycle arrest in a human osteosarcoma cell line. Int J Oncol 31, 915–922.
34 Sowa, Y, Murata, H, Takagi, K, et al. (2007) The plant alkaloid cryptolepine induces p21WAF1/CIP1 and cell cycle arrest in a human osteosarcoma cell line. Int J Oncol 31, 915–922.
35 Aoki, S, Kong, D, Suna, H, Sowa, Y, Sakai, T, Setiawan, A & Kobayashi, M (2006) Aaptamine, a spongean alkaloid, activates p21 promoter in a p53-independent manner. Biochem Biophys Res Commun 342, 101–116.
36 Tarnawski, AS & Jones, MK (1998) The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: involvement of EGF-R signal transduction pathways. J Clin Gastroenterol 27, S12–S20.
37 Sundaram, MV (2006) RTK/Ras/MAPK signaling. WormBook 11, 1–19.
38 Liu, ZM & Huang, HS (2006) As2O3-induced c-Src/EGFR/ERK signaling is via Sp1 binding sites to stimulate p21WAF1/CIP1 expression in human epidermoid carcinoma A431 cells. Cell Signal 18, 244–255.
39 Matsumoto, E, Hatanaka, M, Bohgaki, M & Maeda, S (2006) PKC pathway and ERK/MAPK pathway are required for induction of cyclin D1 and p21Waf1 during 12-o-tetradecanoylphorbol 13-acetate-induced differentiation of myeloleukemia cells. Kobe J Med Sci 52, 181–194.
40 Kuwahara, I, Lillehoj, EP, Lu, W, Singh, IS, Isohama, Y, Miyata, T & Kim, KC (2006) Neutrophil elastase induces IL-8 gene transcription and protein release through p38/NF-κB activation via EGFR transactivation in a lung epithelial cell line. Am J Physiol Lung Cell Mol Physiol 291, 407–416.
41 Matsuo, M, Sakurai, H, Ueno, Y, Ohtani, O & Saiki, I (2006) Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib. Cancer Sci 97, 155–162.
42 Xu, K & Shu, HK (2007) EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res 67, 6121–6129.